gRNA Market: How CRISPR Innovation Is Rewriting the Future of Genetic Engineering
According to a new report by Polaris Market Research, the
global gRNA
market was valued at USD 645.5 million in 2024 and is projected to
reach USD 3,750.8 million by 2034, expanding at a CAGR of 20.40% over the
forecast period. Growth is underpinned by rapid advances in CRISPR-based gene
editing, rising R&D investment in genetic therapies, and expanding demand
for functional genomics research across key end-use industries.
What Is Driving gRNA Market Growth?
Demand is climbing as accelerating genomics and proteomics
research converges with the growing clinical pursuit of personalized medicine.
Researchers and biopharma companies are prioritizing precise, programmable gene
editing, pushing gRNA adoption across drug discovery, cell-line engineering,
and diagnostics. Polaris analysts note that guide RNA's unique ability to
direct CRISPR-Cas systems to specific DNA sequences positions the segment for
sustained high growth through 2034, with pharmaceutical and biotechnology
companies emerging as a leading revenue contributor and custom gRNA synthesis
services posting some of the fastest incremental gains.
Key Trends Shaping the gRNA Industry
Innovations in Proteomics and Genomics Research
Large-scale genomics and proteomics R&D programs
increasingly rely on gRNA to knock out or modulate specific genes, streamlining
target identification and validation. This functional genomics work is
deepening the understanding of gene function and disease mechanisms,
reinforcing gRNA's role as a core research reagent.
Rising Necessity of Personalized Treatment
The application of gRNA technology has advanced on two
fronts: rapid CRISPR-based diagnostic tests and CRISPR-based antiviral
therapeutic research. Heightened public awareness of gene-editing technology,
combined with growing recognition that patients respond differently to the same
treatment, continues to expand market demand for tailored, gRNA-enabled
solutions.
Capacity Expansion and Investment Momentum
Funding and infrastructure activity are accelerating. In
July 2025, BioSpring announced plans to build one of the world's largest RNA
manufacturing facilities dedicated to pharmaceutical-grade guide RNAs, while
AIRNA secured USD 155 million in Series B financing in April 2025 to advance
its guide-RNA-enabled therapeutic pipeline — both signaling growing confidence
in gRNA's clinical-stage potential.
Market Segmentation: Breaking Down the gRNA Market
Polaris segments the gRNA market by product & services,
gRNA type, application, end-use, and region, giving each buyer persona a
standalone, citable data point.
By Product & Services
The products segment led the gRNA market in 2023, favored by
researchers for its high accuracy, efficiency, and specificity in gene editing.
The custom gRNA synthesis services segment is projected to grow at the fastest
pace as biotechnology companies offer researchers tailored design, synthesis,
and delivery options for specific experimental needs.
By gRNA Type
The research-use segment accounted for the largest share in
2023, driven by widespread CRISPR/Cas9 adoption across academic and industry
research programs. The GMP-grade segment is expected to grow at the fastest
rate as demand rises for gRNA manufactured under rigorous quality standards for
clinical trials and patient treatment.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/grna-market
By Application
Genome engineering remains a leading application area,
supported by broad use in gene therapy and cell-line development, while disease
model studies and functional genomics continue to gain share as pharmaceutical
R&D pipelines expand, signaling where near-term demand for research-grade
and GMP-grade gRNA is shifting.
By End-Use
Pharmaceutical and biotechnology companies represent a major
end-use category, reflecting the sector's heavy reliance on gRNA for drug
discovery and therapeutic development, while academic research institutes and
CMOs/CROs continue to broaden the market's end-use base.
Regional Outlook: Where Is the gRNA Market Growing
Fastest?
North America led the market in 2024, supported by a strong
concentration of key players and substantial R&D investment, while Asia
Pacific is expected to post the fastest CAGR through 2034, driven by a large
target population, rapid technology adoption, and Chinese government policies
offering tax incentives and streamlined regulatory pathways for biotech investment.
Within North America, the U.S. remains the largest single market; within Asia
Pacific, China is the primary growth engine. Europe rounds out the top three,
supported by established life sciences infrastructure.
Competitive Landscape: Leading gRNA Companies
Key players profiled in the report include Agilent
Technologies Inc., GENEWIZ (Azenta Life Sciences), Synthego, Thermo Fisher
Scientific Inc., and Merck KGaA, among others, who are focusing on licensing
partnerships and capacity expansion to strengthen market position across the
products and research-use segments outlined above. Recent moves include
BioSpring's large-scale RNA manufacturing investment and AIRNA's Series B
financing round, both aimed at deepening share in the guide-RNA therapeutics
pipeline.
Why It Matters for Buyers Evaluating Market Entry
For stakeholders researching the gRNA market,
this report benchmarks market share, segment-level pricing, and forecast data —
by product & services, gRNA type, application, end-use, and region — to
support sourcing, investment, and go-to-market decisions. It is built for
procurement teams comparing suppliers, investors sizing entry points, and
strategy teams tracking GMP-grade gRNA as a growth adjacency.
About Polaris Market Research
Polaris Market Research is a B2B syndicated market research
and consulting firm offering 5,000+ published reports across 20+ industry
verticals, delivering data-backed insights to help businesses make informed
decisions.
More Trending Latest Reports By Polaris Market Research:
Comments
Post a Comment